Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Sobro in conjunction with an investment in Retune
Mandate

Vinge advises Sobro in conjunction with an investment in Retune

September 28, 2020 Employment and Benefits M&A

Vinge has advised Sobro in conjunction with an investment in Retune, a fast‑growing Swedish IT company which has delivered special competence within cloud, IT infrastructure, IT security and workplace services since 2011.

Retune’s head office is located in Stockholm and the company has approximately 70 employees.

Vinge’s team primarily consisted of Johan Winnerblad, Carl Sander, Elsie Nassar, Fredrika Hjelmberg, Nina Gransäter and Lisa Ullman.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026